Solmaz Assa1, Yoran M Hummel2, Adriaan A Voors2, Johanna Kuipers3, Ralf Westerhuis4, Henk Groen5, Stephan J L Bakker1, Anneke C Muller Kobold6, Wim van Oeveren7, Joachim Struck8, Paul E de Jong1, Casper F M Franssen9. 1. Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 2. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 3. Dialysis Center Groningen, Groningen, the Netherlands. 4. Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Dialysis Center Groningen, Groningen, the Netherlands. 5. Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 6. Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 7. Department of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Haemoscan, Groningen, the Netherlands. 8. B⋅R⋅A⋅H⋅M⋅S, Hennigsdorf, Germany. 9. Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: c.f.m.franssen@umcg.nl.
Abstract
BACKGROUND: Hemodialysis may acutely induce regional left ventricular (LV) systolic dysfunction, which is associated with increased mortality and progressive heart failure. We tested the hypothesis that hemodialysis-induced regional LV systolic dysfunction is associated with inflammation and endothelial injury. Additionally, we studied whether hemodialysis-induced LV systolic dysfunction is associated with an exaggerated bioincompatibility reaction to hemodialysis. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 105 hemodialysis patients on a thrice-weekly dialysis schedule were studied between March 2009 and March 2010. PREDICTORS: Plasma indexes of inflammation (high-sensitivity C-reactive protein, pentraxin 3 [PTX3], interleukin 6 [IL-6], and IL-6:IL-10 ratio), bioincompatibility (leukocytes, neutrophils, complement C3, and myeloperoxidase), and endothelial function (soluble intercellular adhesion molecule 1 [ICAM-1], von Willebrand factor, proendothelin, and endothelin) were measured just before dialysis and at 60, 180, and 240 minutes intradialysis. OUTCOMES: Hemodialysis-induced regional LV systolic function. Wall motion score was measured by echocardiography at 30 minutes predialysis, 60 and 180 minutes intradialysis, and 30 minutes postdialysis. We defined hemodialysis-induced regional LV systolic dysfunction as an increase in wall motion score in 2 or more segments. RESULTS: Patients with hemodialysis-induced regional LV systolic dysfunction (n=29 [27%]) had significantly higher predialysis high-sensitivity C-reactive protein, PTX3, IL-6, and lL-6:IL-10 ratio values. Predialysis levels of bioincompatibility and endothelial markers did not differ between groups. Intradialysis courses of markers of inflammation, bioincompatibility, and endothelial function did not differ in patients with versus without hemodialysis-induced regional LV systolic dysfunction. LIMITATIONS: Coronary angiography or computed tomography for quantification of coronary calcifications in our patients was not performed; therefore, we could not relate markers of inflammation to the extent of atherosclerosis. CONCLUSIONS: Patients with hemodialysis-induced regional LV systolic dysfunction have a proinflammatory cytokine profile. There was no indication of an association with an exaggerated bioincompatibility reaction to hemodialysis.
BACKGROUND: Hemodialysis may acutely induce regional left ventricular (LV) systolic dysfunction, which is associated with increased mortality and progressive heart failure. We tested the hypothesis that hemodialysis-induced regional LV systolic dysfunction is associated with inflammation and endothelial injury. Additionally, we studied whether hemodialysis-induced LV systolic dysfunction is associated with an exaggerated bioincompatibility reaction to hemodialysis. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 105 hemodialysis patients on a thrice-weekly dialysis schedule were studied between March 2009 and March 2010. PREDICTORS: Plasma indexes of inflammation (high-sensitivity C-reactive protein, pentraxin 3 [PTX3], interleukin 6 [IL-6], and IL-6:IL-10 ratio), bioincompatibility (leukocytes, neutrophils, complement C3, and myeloperoxidase), and endothelial function (soluble intercellular adhesion molecule 1 [ICAM-1], von Willebrand factor, proendothelin, and endothelin) were measured just before dialysis and at 60, 180, and 240 minutes intradialysis. OUTCOMES: Hemodialysis-induced regional LV systolic function. Wall motion score was measured by echocardiography at 30 minutes predialysis, 60 and 180 minutes intradialysis, and 30 minutes postdialysis. We defined hemodialysis-induced regional LV systolic dysfunction as an increase in wall motion score in 2 or more segments. RESULTS:Patients with hemodialysis-induced regional LV systolic dysfunction (n=29 [27%]) had significantly higher predialysis high-sensitivity C-reactive protein, PTX3, IL-6, and lL-6:IL-10 ratio values. Predialysis levels of bioincompatibility and endothelial markers did not differ between groups. Intradialysis courses of markers of inflammation, bioincompatibility, and endothelial function did not differ in patients with versus without hemodialysis-induced regional LV systolic dysfunction. LIMITATIONS: Coronary angiography or computed tomography for quantification of coronary calcifications in our patients was not performed; therefore, we could not relate markers of inflammation to the extent of atherosclerosis. CONCLUSIONS:Patients with hemodialysis-induced regional LV systolic dysfunction have a proinflammatory cytokine profile. There was no indication of an association with an exaggerated bioincompatibility reaction to hemodialysis.
Authors: Srisakul Chirakarnjanakorn; Sankar D Navaneethan; Gary S Francis; W H Wilson Tang Journal: Int J Cardiol Date: 2017-01-04 Impact factor: 4.164
Authors: Harmke A Polinder-Bos; Jan Willem J Elting; Marcel Jh Aries; David Vállez García; Antoon Tm Willemsen; Peter J van Laar; Johanna Kuipers; Wim P Krijnen; Riemer Hja Slart; Gert Luurtsema; Ralf Westerhuis; Ron T Gansevoort; Carlo Ajm Gaillard; Casper Fm Franssen Journal: J Cereb Blood Flow Metab Date: 2018-12-12 Impact factor: 6.200
Authors: Scott McGuire; Elizabeth Jane Horton; Derek Renshaw; Alofonso Jimenez; Nithya Krishnan; Gordon McGregor Journal: Biomed Res Int Date: 2018-02-27 Impact factor: 3.411
Authors: Scott McGuire; Elizabeth J Horton; Derek Renshaw; Klaris Chan; Alfonso Jimenez; Helen Maddock; Nithya Krishnan; Gordon McGregor Journal: Clin Kidney J Date: 2019-12-17
Authors: Tori A Stromp; Tyler J Spear; Rebecca M Holtkamp; Kristin N Andres; Joshua C Kaine; Wissam H Alghuraibawi; Steve W Leung; Brandon K Fornwalt; Moriel H Vandsburger Journal: Sci Rep Date: 2018-11-19 Impact factor: 4.379
Authors: Felix Poppelaars; Mariana Gaya da Costa; Bernardo Faria; Stefan P Berger; Solmaz Assa; Mohamed R Daha; José Osmar Medina Pestana; Willem J van Son; Casper F M Franssen; Marc A Seelen Journal: Front Immunol Date: 2018-09-13 Impact factor: 7.561